Factors Influencing the Results of Double-Valve Surgery in Patients with Fulminant Endocarditis: The Importance of Valve Selection

Siniawski, Henryk; Grauhan, O.; Hofmann, Michael; Pašić, Miralem; Weng, Yuguo; Yankah, Charles; Lehmkuhl, H.; Hetzer, Roland

doi:10.1532/hsf98.20041075

Cited by 11 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Indeed, preliminary results in 2003 and 2004 showed that No-React valves resist infection as well as homografts and they were found to have good hemodynamic characteristics. 7,8 In 2008, we reported our results with a larger cohort of 255 patients and the early and midterm results confirmed our expectations. 9 In this study, we have reviewed 402 AIE patients in whom No-React bioprosthesis was implanted between February 2000 and February 2011.…”

Section: Introductionsupporting

confidence: 82%

Further Experience with the “No-React” Bioprosthesis in Patients with Active Infective Endocarditis: 11-Year Single Center Results in 402 Patients

Musci

Amiri

Siniawski

et al. 2013

Thorac cardiovasc Surg

Self Cite

View full text Add to dashboard Cite

Our experience in the use of "No-React" bioprostheses in patients with native and prosthetic AIE shows satisfactory early, midterm, and long-term results, in particular low rates of reoperation due to recurrent endocarditis and SVD. Because these prostheses are readily available and their implantation straightforward, we strongly recommend their use in patients with AIE. Patients' survival differed significantly depending on their surgical urgency. Early mortality was independently predicted by septic shock, abscess formation, and number of implanted valves besides age per 10 years.

show abstract

Section: Introductionsupporting

confidence: 82%

Further Experience with the “No-React” Bioprosthesis in Patients with Active Infective Endocarditis: 11-Year Single Center Results in 402 Patients

Musci

Amiri

Siniawski

et al. 2013

Thorac cardiovasc Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…In valve replacement, the choice of valvular substitute is debated [37]. Beyond biologic and mechanical prostheses, homograft is also an alternative, and is preferably used in periannular abscess, which is often the case in multivalvular IE.…”

Section: Surgical Proceduresmentioning

confidence: 99%

Clinical and Microbiologic Features of Multivalvular Endocarditis

Selton-Suty

Doco‐Lecompte

Bernard

et al. 2010

Curr Infect Dis Rep

View full text Add to dashboard Cite

Multivalvular endocarditis accounts for 15% of all endocarditis. The mechanisms of spread of the infection differs whether endocarditis is only left-sided (involving both the mitral and aortic valves) or bilateral. In left-sided bivalvular endocarditis, it is often a secondary mitral lesion following a primary aortic endocarditis. Multivalvular endocarditis often results in severe and extensive cardiac lesions, well described at echocardiography and frequently responsible for severe heart failure. Patients often need surgery, which consists of radical debridement of all the infected tissue with reconstruction using different types of prostheses; therefore, the surgery may be very complex. The goal should be an early diagnosis of endocarditis to avoid spread of the infection to more than one valve, to improve the prognosis for those patients.

show abstract

“…Further studies using No-React ® tissue as a patch for the Norwood procedure caused no anti-HLA antibodies whereas allografts induced the production of antibodies [ 13 ]. Indeed, clinical studies with No-React ® valves, receiving an identical treatment to the No-React ® BioConduit, have shown a high resistance to infection [ 14 , 15 ]. However, a recent report has warned on the possibility that this valved conduit may undergo degeneration [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Totally biological composite aortic stentless valved conduit for aortic root replacement: 10-year experience

Galiñanes

Meduoye

Ferreira

et al. 2011

J Cardiothorac Surg

View full text Add to dashboard Cite

ObjectivesTo retrospectively analyze the clinical outcome of a totally biological composite stentless aortic valved conduit (No-React® BioConduit) implanted using the Bentall procedure over ten years in a single centre.MethodsBetween 27/10/99 and 19/01/08, the No-React® BioConduit composite graft was implanted in 67 patients. Data on these patients were collected from the in-hospital database, from patient notes and from questionnaires. A cohort of patients had 2D-echocardiogram with an average of 4.3 ± 0.45 years post-operatively to evaluate valve function, calcification, and the diameter of the conduit.ResultsImplantation in 67 patients represented a follow-up of 371.3 patient-year. Males were 60% of the operated population, with a mean age of 67.9 ± 1.3 years (range 34.1-83.8 years), 21 of them below the age of 65. After a mean follow-up of 7.1 ± 0.3 years (range of 2.2-10.5 years), more than 50% of the survivors were in NYHA I/II and more than 60% of the survivors were angina-free (CCS 0). The overall 10-year survival following replacement of the aortic valve and root was 51%. During this period, 88% of patients were free from valved-conduit related complications leading to mortality. Post-operative echocardiography studies showed no evidence of stenosis, dilatation, calcification or thrombosis. Importantly, during the 10-year follow-up period no failures of the valved conduit were reported, suggesting that the tissue of the conduit does not structurally change (histology of one explant showed normal cusp and conduit).ConclusionsThe No-React® BioConduit composite stentless aortic valved conduit provides excellent long-term clinical results for aortic root replacement with few prosthesis-related complications in the first post-operative decade.

show abstract

Factors Influencing the Results of Double-Valve Surgery in Patients with Fulminant Endocarditis: The Importance of Valve Selection

Cited by 11 publications

References 16 publications

Further Experience with the “No-React” Bioprosthesis in Patients with Active Infective Endocarditis: 11-Year Single Center Results in 402 Patients

Further Experience with the “No-React” Bioprosthesis in Patients with Active Infective Endocarditis: 11-Year Single Center Results in 402 Patients

Clinical and Microbiologic Features of Multivalvular Endocarditis

Totally biological composite aortic stentless valved conduit for aortic root replacement: 10-year experience

Contact Info

Product

Resources

About